GlaxoSmithKline has an active research and development program targeted at both seasonal and pandemic flu and has recently invested more than $2 billion to expand capacity for manufacturing its flu vaccines FLUARIX and FLULAVAL and its antiviral flu medication RELENZA® (Zanamivir).
 

GlaxoSmithKline: A Leader in Vaccines
 

GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline's vaccines business, is one of the world's leading vaccine companies and a leader in innovation. The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development.
 

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information go to us.gsk.com, follow us on twitter.com/GSKUS or visit our blog (www.morethanmedicine.us.gsk.com/blog/).
 

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2009.
 

Source: GlaxoSmithKline

CONTACT: US Media Inquiries: Nancy Pekarek, +1-919-483-2839, Mary Anne
Rhyne, +1-919-483-2839, Kevin Colgan, +1-919-483-2839, or Sarah Alspach,
+1-919-483-2839; US Analyst/ Investor Inquiries: Tom Curry, +1-215-751-5419,
or Jen Hill Baxter, +1-215-751-7002